Mechanism of action
Ephedrine is a mixed-action sympathomimetic with both direct and indirect effects on the sympathetic nervous system.
Direct effects
Ephedrine acts as a direct agonist at α1, α2, β1, and β2 adrenergic receptors, though with lower potency than catecholamines. The α1 stimulation produces vasoconstriction and increases peripheral vascular resistance. β1 stimulation increases heart rate and myocardial contractility. β2 stimulation causes bronchodilation and skeletal muscle vasodilation.
Indirect effects
Ephedrine enters sympathetic nerve terminals and displaces norepinephrine from presynaptic storage vesicles, increasing synaptic norepinephrine concentrations. This indirect mechanism accounts for much of its cardiovascular effect. Unlike direct-acting catecholamines, ephedrine's effects depend on adequate neuronal norepinephrine stores.
Tachyphylaxis
Repeated dosing leads to depletion of norepinephrine stores, resulting in progressively diminished response (tachyphylaxis). This typically develops within hours to days of continuous use. The direct receptor effects persist, but the more pronounced indirect effects fade.
- Ephedrine is a mixed-action sympathomimetic with direct α/β agonism and indirect norepinephrine release.
- Tachyphylaxis develops rapidly with repeated dosing due to depletion of presynaptic norepinephrine stores.
- Unlike catecholamines, ephedrine resists MAO and COMT breakdown, allowing oral administration and longer duration.
- Ephedrine crosses the blood-brain barrier and placenta, unlike norepinephrine or epinephrine.
- Combination with MAO inhibitors causes hypertensive crisis by excessive norepinephrine accumulation.
- Phenylephrine is preferred over ephedrine for obstetric hypotension; ephedrine is associated with fetal acidosis.
- Urinary pH affects elimination: acidic urine increases clearance, alkaline urine prolongs half-life.
- Non-selective β-blockers with ephedrine cause unopposed α-stimulation and paradoxical severe hypertension.
Indications
Perioperative hypotension: Ephedrine is widely used to treat hypotension during spinal or epidural anesthesia, particularly in obstetric anesthesia. It maintains uterine blood flow better than pure α-agonists due to its mixed α and β effects.
Nasal congestion: Topical and oral formulations are used as nasal decongestants. The α1-mediated vasoconstriction reduces mucosal edema and improves nasal airflow.
Bronchospasm: Historically used for asthma and bronchospasm due to β2-agonist effects, though largely replaced by more selective β2-agonists like albuterol.
Orthostatic hypotension: Occasionally used off-label for chronic orthostatic hypotension when other measures fail.
Narcolepsy: Previously used for its central nervous system stimulant effects, now replaced by newer agents.
Dosing follows the product label and varies by indication and route of administration.
Pharmacokinetics
Absorption: Ephedrine is well absorbed orally with bioavailability approaching 85-90%. Peak plasma concentrations occur 1-2 hours after oral administration. It is also effective via intramuscular, intravenous, and topical routes.
Distribution: Ephedrine crosses the blood-brain barrier due to its lipophilic nature, producing central nervous system stimulation. It also crosses the placenta.
Metabolism: Unlike catecholamines, ephedrine is not a substrate for monoamine oxidase (MAO) or catechol-O-methyltransferase (COMT). This accounts for its longer duration of action and oral activity. It undergoes hepatic N-demethylation and oxidative deamination, with some metabolism to norephedrine.
Excretion: Approximately 60-75% is excreted unchanged in urine. Elimination is highly pH-dependent: acidic urine (pH < 6) increases ionization and renal clearance, shortening the half-life to 3 hours. Alkaline urine decreases clearance, extending the half-life to 6 hours or longer.
Half-life: 3-6 hours, varying with urinary pH.
Adverse effects
Cardiovascular
- Tachycardia and palpitations from β1 stimulation
- Hypertension from α1-mediated vasoconstriction
- Arrhythmias, including ventricular ectopy
- Myocardial ischemia in patients with coronary artery disease
- Reflex bradycardia may occur with significant hypertension
Central nervous system
- Anxiety, restlessness, nervousness
- Insomnia when taken late in the day
- Tremor from β2 stimulation
- Headache
- Dizziness
- Seizures at toxic doses or in susceptible individuals
Other effects
- Urinary retention from α1 stimulation of bladder neck
- Mydriasis and difficulty with accommodation
- Hyperglycemia from β2-mediated glycogenolysis
- Hypokalemia from β2-stimulated cellular potassium uptake
- Nausea and vomiting
- Difficulty urinating in men with prostatic hypertrophy
Tolerance and dependence
Tachyphylaxis develops with repeated use. Psychological dependence may occur with chronic use due to CNS stimulant properties.
Contraindications and warnings
Absolute contraindications
- Hypersensitivity to ephedrine or sympathomimetics
- Concurrent or recent MAO inhibitor use (within 14 days): risk of hypertensive crisis
- Severe hypertension or uncontrolled hypertension
- Severe coronary artery disease or recent myocardial infarction
- Narrow-angle glaucoma
- Thyrotoxicosis
- Pheochromocytoma (relative contraindication)
Warnings and precautions
Cardiovascular disease: Use with extreme caution in patients with ischemic heart disease, arrhythmias, heart failure, or aortic stenosis. May precipitate angina or myocardial infarction.
Hypertension: Monitor blood pressure closely. Ephedrine can cause significant hypertensive responses, particularly in hypertensive patients or with excessive dosing.
Diabetes mellitus: May increase blood glucose and interfere with glycemic control.
Prostatic hypertrophy: α1 stimulation can worsen urinary obstruction.
Hyperthyroidism: Enhanced sensitivity to sympathomimetics increases risk of cardiovascular complications.
Pregnancy: Category C. Crosses the placenta and may cause fetal tachycardia. Used cautiously for hypotension during obstetric anesthesia when maternal blood pressure is critical.
Elderly patients: Increased sensitivity to cardiovascular and CNS effects.
Athletic use: Ephedrine is banned by most sports organizations as a performance-enhancing stimulant.
Drug interactions
MAO inhibitors
Severe interaction: MAOIs prevent the breakdown of norepinephrine, and ephedrine's indirect mechanism further increases synaptic norepinephrine. This combination can cause life-threatening hypertensive crisis. Avoid concurrent use and allow 14 days after MAOI discontinuation.
Tricyclic antidepressants
TCAs inhibit norepinephrine reuptake, potentiating ephedrine's indirect effects. Risk of severe hypertension and arrhythmias. Use together cautiously with blood pressure monitoring.
Other sympathomimetics
Additive cardiovascular effects (tachycardia, hypertension, arrhythmias) when combined with other stimulants or decongestants.
β-blockers
Non-selective β-blockers may lead to unopposed α-stimulation, causing paradoxical severe hypertension. Selective β1-blockers have less risk but still may attenuate ephedrine's beneficial effects.
α-blockers
α-blockers (prazosin, terazosin, doxazosin) may antagonize the vasopressor effects of ephedrine, reducing its efficacy for hypotension.
Cardiac glycosides
Concurrent use with digoxin increases risk of arrhythmias due to additive effects on cardiac automaticity.
Urinary acidifiers and alkalinizers
Acidification (ammonium chloride, ascorbic acid in large doses) increases renal clearance and shortens duration. Alkalinization (sodium bicarbonate, acetazolamide) decreases clearance and prolongs action.
Theophylline
Additive CNS stimulation and increased risk of cardiovascular adverse effects.
Antihypertensives
Ephedrine may reduce the effectiveness of antihypertensive medications through its pressor effects.
Halogenated anesthetics
May sensitize the myocardium to catecholamines, increasing arrhythmia risk during anesthesia.
Clinical pearls
Ephedrine vs. phenylephrine in obstetrics: While ephedrine's β effects maintain cardiac output and uterine blood flow, phenylephrine is now preferred as first-line for spinal anesthesia-induced hypotension in pregnancy because ephedrine is associated with higher risk of fetal acidosis.
Tachyphylaxis management: When tachyphylaxis develops (usually after 2-3 doses within hours), switching to a direct-acting vasopressor like phenylephrine or norepinephrine is more effective than increasing ephedrine doses.
Urinary pH matters: In poisoning or when prolonged effect is problematic, urinary acidification accelerates elimination. Conversely, alkaline urine prolongs ephedrine action.
CNS penetration: Unlike catecholamines (norepinephrine, epinephrine), ephedrine crosses the blood-brain barrier, causing CNS stimulation (insomnia, anxiety). This makes it unsuitable for patients sensitive to stimulants.
Not a catecholamine: Ephedrine lacks the catechol structure, making it resistant to MAO and COMT. This explains its oral bioavailability and longer duration compared to epinephrine or norepinephrine.
Dietary supplement history: Ephedrine and its analogue ephedra were widely available as weight-loss and athletic performance supplements until banned by the FDA in 2004 due to cardiovascular risks.
Testing norepinephrine stores: Ephedrine can serve as an indirect test of sympathetic nerve function. Absent response to ephedrine but intact response to norepinephrine suggests sympathetic denervation or depleted stores.
Chronic use caution: Long-term use risks cardiovascular complications, psychological dependence, and complete tachyphylaxis requiring escalating doses. Reserve for acute, short-term indications.
Neonatal effects: When used near delivery, ephedrine can cross the placenta and cause neonatal tachycardia and irritability, though these effects are usually transient.
Practice questions
1. A 32-year-old woman at 38 weeks gestation undergoes spinal anesthesia for cesarean delivery. Five minutes after the block, her blood pressure drops to 80/50 mmHg. She receives intravenous ephedrine, which restores her blood pressure to 110/70 mmHg. Twenty minutes later, her blood pressure again falls to 85/55 mmHg. A second dose of ephedrine produces minimal effect. Which of the following best explains the diminished response to the second dose?
2. A 58-year-old man with a history of depression is brought to the emergency department with severe headache, diaphoresis, and blood pressure of 220/130 mmHg. He reports taking an over-the-counter supplement containing ephedrine for weight loss. His medication list includes phenelzine, which he started 10 days ago. Which of the following best explains this patient's presentation?
3. A 45-year-old woman with asthma and hypertension controlled on propranolol presents to the emergency department with acute bronchospasm. She is given ephedrine for bronchodilation and blood pressure support. Shortly after administration, her blood pressure increases to 200/115 mmHg. Which of the following mechanisms best explains this severe hypertensive response?
Frequently asked questions
How does ephedrine work?
Ephedrine works through a dual mechanism: it directly stimulates α1, α2, β1, and β2 adrenergic receptors, and indirectly releases norepinephrine from presynaptic nerve terminals. The direct effects cause vasoconstriction (α1), increased heart rate and contractility (β1), and bronchodilation (β2). The indirect mechanism accounts for much of its cardiovascular effect by increasing synaptic norepinephrine concentrations. Unlike catecholamines, ephedrine is not metabolized by MAO or COMT, giving it a longer duration and allowing oral administration.
What are the side effects of ephedrine?
Common side effects include tachycardia, palpitations, hypertension, anxiety, nervousness, insomnia, tremor, headache, and dizziness. Cardiovascular effects like arrhythmias and myocardial ischemia can occur, particularly in patients with underlying heart disease. Central nervous system stimulation causes restlessness and can lead to seizures at high doses. Other effects include urinary retention (especially in men with prostatic hypertrophy), mydriasis, hyperglycemia, and hypokalemia. Tachyphylaxis develops with repeated use, requiring increasing doses for the same effect.
Is ephedrine a controlled substance?
Ephedrine is not classified as a controlled substance under the Controlled Substances Act in the United States, but it is a regulated chemical under the Combat Methamphetamine Epidemic Act (CMEA) of 2005. This regulation exists because ephedrine can be used as a precursor in illegal methamphetamine synthesis. Purchases are limited in quantity, require identification, and sales are tracked. Medical use requires a prescription in most jurisdictions. It is also banned by most sports organizations as a performance-enhancing stimulant.
Ephedrine vs phenylephrine — what is the difference?
Ephedrine is a mixed-action sympathomimetic with both direct receptor agonism (α and β) and indirect norepinephrine release, while phenylephrine is a selective direct α1-agonist with no indirect effects. Ephedrine increases heart rate and cardiac output (β1 effects) and causes bronchodilation (β2 effects), whereas phenylephrine causes pure vasoconstriction often with reflex bradycardia. Ephedrine undergoes tachyphylaxis with repeated dosing because it depletes norepinephrine stores; phenylephrine does not. In obstetric anesthesia, phenylephrine is now preferred because ephedrine is associated with higher risk of fetal acidosis, though both are effective for treating hypotension.
Why does ephedrine cause tachyphylaxis?
Tachyphylaxis occurs because ephedrine's indirect mechanism depends on releasing presynaptic norepinephrine stores from sympathetic nerve terminals. With repeated dosing over hours to days, these norepinephrine stores become depleted, and the indirect component of ephedrine's action progressively weakens. The direct receptor agonist effects persist, but since the indirect mechanism accounts for much of the cardiovascular response, overall efficacy diminishes. This is why switching to a purely direct-acting agent like phenylephrine or norepinephrine becomes necessary when ephedrine loses effectiveness after multiple doses.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: R01AA03WHO ATC/DDD index: C01CA26
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.